Cargando...
Alternate sunitinib schedules in patients with metastatic renal cell carcinoma
Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor exhibiting antiangiogenic activity. Sunitinib demonstrated improved outcomes in comparison to interferon-α in a large phase III study of treatment naïve patients with metastatic renal cell carcinoma. Maintaining patients on sunitini...
Guardado en:
| Publicado en: | Ann Oncol |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Oxford University Press
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4490228/ https://ncbi.nlm.nih.gov/pubmed/25628443 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv030 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|